These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18790526)

  • 1. Timeframe for thrombolysis in acute ischaemic stroke.
    Tsivgoulis G; Alexandrov AV
    Lancet; 2008 Oct; 372(9646):1275-6. PubMed ID: 18790526
    [No Abstract]   [Full Text] [Related]  

  • 2. A response to "Dental implications of acute stroke therapy and anticoagulation for stroke prevention".
    Stoopler ET
    Compend Contin Educ Dent; 2010 Jun; 31(5):322. PubMed ID: 20583500
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous tissue plasminogen activator thrombolysis in patients with diabetes mellitus and previous stroke.
    Gonzalez-Hernandez AN; Fabre-Pi O; Lopez-Fernandez JC; Diaz-Nicolas S
    Stroke; 2009 Dec; 40(12):e707; author reply e708. PubMed ID: 19875737
    [No Abstract]   [Full Text] [Related]  

  • 4. Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain?
    Buchan AM; Feasby TE
    CMAJ; 2000 Jan; 162(1):47-8. PubMed ID: 11216198
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrent ischemic stroke can happen in stroke patients very early after intravenous thrombolysis.
    Kamal H; Mowla A; Farooq S; Shirani P
    J Neurol Sci; 2015 Nov; 358(1-2):496-7. PubMed ID: 26375625
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
    van Hooff RJ; Nieboer K; De Smedt A; Yperzeele L; Jochmans K; De Keyser J; Brouns R
    Clin Neurol Neurosurg; 2014 Jul; 122():133-4. PubMed ID: 24813326
    [No Abstract]   [Full Text] [Related]  

  • 7. [Can the target group for thrombolysis in acute ischemic stroke be widened? Current indication is very narrow--new study results are necessary].
    Murray V
    Lakartidningen; 2011 Jan 12-18; 108(1-2):16-7. PubMed ID: 21365808
    [No Abstract]   [Full Text] [Related]  

  • 8. Neurothrombectomy in acute ischaemic stroke: a prospective single-centre study and comparison with randomized controlled trials.
    Nikoubashman O; Jungbluth M; Schürmann K; Müller M; Falkenburger B; Tauber SC; Wiesmann M; Schulz JB; Reich A
    Eur J Neurol; 2016 Apr; 23(4):807-16. PubMed ID: 26850793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
    Wahlgren N; Ahmed N; Dávalos A; Hacke W; Millán M; Muir K; Roine RO; Toni D; Lees KR;
    Lancet; 2008 Oct; 372(9646):1303-9. PubMed ID: 18790527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated weight is not a reliable measure for dosing tissue plasminogen activator for thrombolysis in acute ischaemic stroke.
    Gill D; Halsey L; Kalkat H; Patel S; Kar A
    Int J Stroke; 2016 Feb; 11(2):NP25-6. PubMed ID: 26783320
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of tissue plasminogen activator to treat acute ischemic stroke.
    Alexandrov AW
    Crit Care Nurse; 2010 Oct; 30(5):77-8. PubMed ID: 20889516
    [No Abstract]   [Full Text] [Related]  

  • 12. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
    Wechsler LR
    Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061
    [No Abstract]   [Full Text] [Related]  

  • 13. Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis.
    Hosoki S; Takagi M; Yamagami H; Ando D; Toyoda K; Koga M
    J Neurol; 2018 Oct; 265(10):2451-2453. PubMed ID: 30116941
    [No Abstract]   [Full Text] [Related]  

  • 14. Is it justified to exclude patients with minor stroke from intravenous thrombolysis?
    García-García J; Ayo-Martín O; Segura T
    Int J Stroke; 2013 Apr; 8(3):E4. PubMed ID: 23489669
    [No Abstract]   [Full Text] [Related]  

  • 15. Timing of thrombolysis for acute ischaemic stroke: the earlier the treatment the better the outcome, irrespective of age or stroke severity.
    Lorenzano S
    Evid Based Med; 2015 Jun; 20(3):108. PubMed ID: 25854628
    [No Abstract]   [Full Text] [Related]  

  • 16. Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience.
    Uyttenboogaart M; Schrijvers EM; Vroomen PC; De Keyser J; Luijckx GJ
    Age Ageing; 2007 Sep; 36(5):577-9. PubMed ID: 17405776
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombolysis 3 to 4.5 hours after acute ischemic stroke.
    Fitzpatrick AE; Noone I; O'Shea DD
    N Engl J Med; 2008 Dec; 359(26):2840; author reply 2841. PubMed ID: 19115491
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombolysis 3 to 4.5 hours after acute ischemic stroke.
    Morris DC
    N Engl J Med; 2008 Dec; 359(26):2841; author reply 2841. PubMed ID: 19115492
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombolysis 3 to 4.5 hours after acute ischemic stroke.
    Torbey MT; Jauch E; Liebeskind DS;
    N Engl J Med; 2008 Dec; 359(26):2839; author reply 2841. PubMed ID: 19109580
    [No Abstract]   [Full Text] [Related]  

  • 20. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
    Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
    Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.